Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has two wholly-owned ADCs that are on clinical pathways and two high value collaborations with Celgene and Merck Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA 2019. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated early anti-tumor activity in patients with advanced R&R ovarian cancer.
Phase l or ll
100MM - 500MM
Antibodies, Platform Technology
310 Utah Ave
South San Francisco, CA 94080
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by